Group 1 - The primary goal of the "High Income DIY Portfolios" service is to provide high income with low risk and capital preservation for DIY investors [1] - The service offers seven portfolios designed for income investors, including retirees, featuring three buy-and-hold portfolios, three rotational portfolios, and a conservative NPP strategy portfolio [1] - The portfolios include two high-income portfolios, two dividend growth investing (DGI) portfolios, and a conservative NPP strategy portfolio aimed at low drawdowns and high growth [1] Group 2 - The "High Income DIY Portfolios" service includes a total of 10 model portfolios with varying income targets and risk levels, along with buy and sell alerts and live chat support [2] - The investment approach focuses on dividend-growing stocks with a long-term horizon, aiming for 30% lower drawdowns and 6% current income [2] - The service is managed by a financial writer with 25 years of investment experience, emphasizing strategies for stable, long-term passive income [2]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 ______________________________________________ FORM 10-K (MARK ONE) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 Commission file number 1-2189 Abbott Laboratories An Illinois Corporation 36-0698440 100 Abbott Park Road Abbott Park, Illinois 600 ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corporation (NASDAQ: EXAS) ("Exact Sciences†), a leading provider of cancer screening and diagnostic tests, today announced that its stockholders voted to approve the proposed acquisition of Exact Sciences by Abbott (NYSE: ABT) at the special meeting of stockholders held earlier today. At the special meeting, preliminary results showed that more than 99% of the votes cast, representing approximately 67% of the total outstanding shares of Exact Scie. ...

Abbott declares 409th consecutive quarterly dividend [Accessibility Statement] Skip NavigationABBOTT PARK, Ill., Feb. 20, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share.This marks the 409th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable May 15, 2026, to shareholders of record at the close of business on April 15, 2026.Abbott has increased its dividend payout for [54 consecutive y ...

Key Takeaways ABT appears more attractive on valuation and recent performance in this MedTech comparison.BSX posted 14% Q4 operational sales growth, with strength in EP, WATCHMAN and oncology.Abbott saw strong CGM sales above $7.5B in 2025 and expanded via the Exact Sciences deal.Among large-cap U.S. MedTech companies, Boston Scientific (BSX) and Abbott (ABT) continue to attract significant investor focus. Abbott’s business model is diversified, having leading businesses and products in diagnostics, medical ...

LISTING LINK: https://www.premiersothebysrealty.com/single-family/mfr/a4681242/6610-gulf-of-mexico-drive-longboat-key-fl-34228 DROPBOX: https://tours.coastalhomephotography.net/public/vtour/display/2359971?idx=1#!/nav/gallery PHOTO CREDIT: Coastal Home Photography LONGBOAT KEY, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Located on the north end of Longboat Key, 6610 and 6630 Gulf of Mexico Drive comprise a rare, nearly five-acre bayfront estate offering exceptional scale, architectural distinction, and long-te ...

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Core Viewpoint - Nestlé SA is increasing production of infant formula to prevent shortages following a contamination crisis that led to a significant recall of products from multiple companies, including Danone SA and Groupe Lactalis [1][3]. Production and Supply Chain - Five Nestlé factories in France, Spain, Germany, Switzerland, and the Netherlands are operating 24/7 to enhance supply, particularly for infants under one year old [2]. - The production boost is a response to the ongoing infant formula crisis, which has seen products from at least five companies recalled in over 60 countries due to contamination concerns [3]. - Other manufacturers, such as HiPP and Holle, are also increasing production to meet rising demand, despite not being affected by the recall [3][9]. Market Impact and Investor Reaction - The recall has negatively impacted publicly-listed formula producers, with stock prices dropping in response to investigations into potential health risks associated with the formula [4][5]. - Nestlé's shares experienced a slight decline, while Danone's stock remained stable after reports indicated no poisoning cases in China, a significant market for Danone [5][6]. Regulatory Actions - China's market regulator has mandated formula makers to test for cereulide, which may help restore investor confidence in the industry [6]. - The investigation into a potential link between a third baby's death in France and Nestlé's formula has further pressured the companies' stock prices [5]. Industry Dynamics - The infant formula market is dominated by major companies, including Nestlé, Danone, and Reckitt Benckiser Group's Mead Johnson, which collectively hold 35% of the global market [9]. - The high market concentration makes it challenging for parents to switch brands, especially during recalls, as many are reluctant to change products that their babies are accustomed to [9]. Production Stability - Other producers, including Danone and Groupe Lactalis, have reported no signs of shortages and are maintaining their current production levels [11]. - Companies like DMK and Hochdorf, which were affected by the contamination recalls, are also keeping their production steady [11].

Core Insights - Abbott Laboratories has raised its quarterly dividend to $0.63, marking a 6.8% increase from the previous rate, with a free cash flow payout ratio of 60.4% [1][2] - The company has a consistent dividend growth streak of 13 years, with total annual payout increasing from $1.04 in 2016 to $2.36 in 2025, representing a 127% increase [1] - Despite a 9.8% decline in shares year-to-date, the current dividend yield of 2.14% is considered attractive for income investors [1] Dividend Growth - Abbott has increased its dividend for 13 consecutive years, with a compound annual growth rate of 9.2% over the past decade [1] - The recent quarterly increase from $0.59 to $0.63 continues the trend, although growth rates have moderated compared to earlier in the decade [1] - CEO Robert Ford reaffirmed the company's commitment to growing dividends during the recent earnings call [1] Cash Flow Coverage - In fiscal 2024, Abbott generated $8.56 billion in operating cash flow and $6.35 billion in free cash flow, with a 60.4% free cash flow payout ratio [1] - The payout ratio increased from 42.4% in 2022, reflecting both growing dividend commitments and declining cash generation due to reduced COVID-related testing revenue [1] - Quarterly free cash flow payout ratios showed volatility, with a peak of 110% in Q1 2025, but normalized in subsequent quarters [1] Profitability Metrics - Abbott maintains a 22% operating margin and a 14.7% profit margin, with a return on equity of 13.2%, supporting dividend sustainability [1] - The FreeStyle Libre glucose sensor recall, classified as a Class I recall, poses risks to profitability and may lead to litigation costs [1] - The medical devices segment showed a 12.3% growth in Q4, with strong performance from electrophysiology products [1] Forward Guidance - Management's guidance for 2026 includes an adjusted EPS of $5.55-$5.80, indicating approximately 10% growth at the midpoint [1] - Expected organic sales growth is projected at 6.5-7.5%, with annual margin expansion of 50-70 basis points [1] - The nutrition segment, which declined 8.9% in Q4, is anticipated to face challenges in the first half of 2026 before recovery [1] Valuation and Peer Comparison - Abbott's trailing P/E ratio is 30x, while the forward P/E is 20x, suggesting potential normalization as earnings grow [2] - Compared to Johnson & Johnson's 2.16% dividend yield and 46.6% payout ratio, Abbott's 63.8% payout ratio indicates less cushion but remains sustainable [2] - Institutional investors hold 81.7% of Abbott's shares, reflecting confidence in the company's long-term prospects despite current challenges [2]

Summary of China Medtech Q425 Conference Call Industry Overview - **Industry**: Medical Technology (Medtech) in China - **Context**: The conference call discusses the performance of various global medtech companies in China during Q425, highlighting ongoing challenges and opportunities in the market for 2026. Key Points 1. Overall Market Sentiment - Many large-cap global medtech companies reported a year-over-year (YoY) decline in China revenue for Q425, particularly in the diagnostics (Dx) sector. Companies expect policy headwinds to persist into 2026, albeit at a reduced impact level [2][4] 2. Equipment Sector Performance - **GE Healthcare**: Reported an 11% YoY revenue decline in China for Q425, with flat revenue quarter-over-quarter (QoQ). The company noted improved VBP (Volume-Based Procurement) win rates and a stronger imaging funnel but still anticipates a decline in 2026 revenue guidance for the China business [3][4] - **Siemens Healthineers**: Experienced a 5% YoY decline in China revenue for Q425, with imaging and precision therapy segments remaining flat. The Dx revenue sharply fell due to VBP and reimbursement cuts, with expectations of a flat volume development for the non-Dx business in FY26 [3][4] - **Intuitive Surgical**: Reported a drop in placements in China from 20 to 17 in Q425, citing intensified competition from local suppliers and lower pricing in provincial tenders [3] 3. Diagnostics Sector Challenges - **Roche**: The China Dx segment faced a 12% YoY revenue decline in Q425, with core lab oncology reagents down approximately 50% in 2025. The company expects continued but diminishing headwinds in 2026 [4] - **Abbott**: Estimated a US$400 million headwind from VBPs, indicating that most of its Dx sales in China have already been affected by these reforms [4] - **Danaher**: Reported a low single-digit decline in core revenue in China for Q425, with Dx segment under pressure from policy headwinds. The company anticipates a moderation of VBP impacts in 2026 [4] 4. Consumables Sector Growth - **Boston Scientific**: Achieved double-digit revenue growth in China for Q425, driven by electrophysiology (EP) and interventional cardiology therapies. The company expects this momentum to continue into 2026, supported by recent NMPA approvals [5] - **Johnson & Johnson**: Continues to face negative impacts from VBPs across its surgery and orthopaedics portfolio, with expectations of additional rounds of VBPs in 2026 [5] Additional Insights - The medtech industry in China faces several risks, including larger-than-expected price reductions from VBP programs, weaker demand from equipment renewal programs, and geopolitical issues affecting supply chains [8] - The overall sentiment indicates a cautious outlook for 2026, with companies adapting to ongoing policy changes and competitive pressures in the Chinese market [2][4][5]